The aim of our study was to evaluate sclerostin concentrations in patients with abnormal thyroid functions (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and healthy euthyroid subjects, as well as to analyze the relationship between sclerostin concentrations and markers of bone metabolism (osteocalcin and beta-cross-laps). The gene discussed is BGLAP; the disease is hypothyroidism.